Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca’s Gout Drug Lesinurad Hobbled By Renal Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

Lower dose of oral, uric acid transporter inhibitor shows good efficacy in two of three Phase III trials, but renal safety risk appears to limit lesinurad’s potential market – if it gets approved at all.

You may also be interested in...



With Zurampic, FDA Again Made Do With Sorry State Of Regulatory Science In Gout

Zurampic, which AstraZeneca licensed to Ironwood, pushed the limits of FDA's tolerance of the regulatory compromises agency has had to make in gout; our Drug Review Profile shows how statistician's case against approval received serious consideration, although the agency ultimately valued consistency with previous approvals in the space.

AstraZeneca's Gout Dilemma: Should Smaller, More Frequent Lesinurad Dose Be Studied?

FDA is concerned about product's narrow therapeutic index, but advisory committee says it’s not an issue for approval; could this be addressed in post-marketing trial?

AstraZeneca’s Gout Drug Lesinurad May Face Risk Management Issues

Company already offering boxed warning and post-marketing cardiovascular study as advisory committee meeting nears.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel